- Home
- BMEZ vs RCUS Comparison
BMEZ vs RCUS Comparison
Compare BMEZ & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEZ
- RCUS
- Stock Information
- Founded
- BMEZ N/A
- RCUS 2015
- Country
- BMEZ United States
- RCUS United States
- Employees
- BMEZ N/A
- RCUS N/A
- Industry
- BMEZ Trusts Except Educational Religious and Charitable
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BMEZ Finance
- RCUS Health Care
- Exchange
- BMEZ Nasdaq
- RCUS Nasdaq
- Market Cap
- BMEZ 1.5B
- RCUS 1.4B
- IPO Year
- BMEZ N/A
- RCUS 2018
- Fundamental
- Price
- BMEZ $15.28
- RCUS $14.02
- Analyst Decision
- BMEZ
- RCUS Buy
- Analyst Count
- BMEZ 0
- RCUS 12
- Target Price
- BMEZ N/A
- RCUS $34.50
- AVG Volume (30 Days)
- BMEZ 391.3K
- RCUS 609.3K
- Earning Date
- BMEZ 01-01-0001
- RCUS 02-19-2025
- Dividend Yield
- BMEZ 8.71%
- RCUS N/A
- EPS Growth
- BMEZ N/A
- RCUS N/A
- EPS
- BMEZ 0.54
- RCUS N/A
- Revenue
- BMEZ N/A
- RCUS $263,000,000.00
- Revenue This Year
- BMEZ N/A
- RCUS $127.65
- Revenue Next Year
- BMEZ N/A
- RCUS N/A
- P/E Ratio
- BMEZ $30.17
- RCUS N/A
- Revenue Growth
- BMEZ N/A
- RCUS 119.17
- 52 Week Low
- BMEZ $12.93
- RCUS $13.51
- 52 Week High
- BMEZ $16.95
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- BMEZ 53.02
- RCUS 37.13
- Support Level
- BMEZ $15.16
- RCUS $13.81
- Resistance Level
- BMEZ $15.52
- RCUS $14.52
- Average True Range (ATR)
- BMEZ 0.24
- RCUS 0.60
- MACD
- BMEZ 0.06
- RCUS -0.09
- Stochastic Oscillator
- BMEZ 79.53
- RCUS 22.97
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.